Millennium Pharmacon International Stock Current Valuation
| SDPC Stock | IDR 154.00 4.00 2.53% |
Valuation analysis of Millennium Pharmacon helps investors to measure Millennium Pharmacon's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Millennium Pharmacon's price fluctuation is very steady at this time. Calculation of the real value of Millennium Pharmacon is based on 3 months time horizon. Increasing Millennium Pharmacon's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Millennium Pharmacon's intrinsic value may or may not be the same as its current market price of 154.00, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 154.0 | Real 130.62 | Hype 158.0 |
The intrinsic value of Millennium Pharmacon's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Millennium Pharmacon's stock price.
Estimating the potential upside or downside of Millennium Pharmacon International helps investors to forecast how Millennium stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Millennium Pharmacon more accurately as focusing exclusively on Millennium Pharmacon's fundamentals will not take into account other important factors: Millennium Pharmacon International Company Current Valuation Analysis
Millennium Pharmacon's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Millennium Pharmacon Current Valuation | 828.27 B |
Most of Millennium Pharmacon's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Millennium Pharmacon International is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Millennium Pharmacon International has a Current Valuation of 828.27 B. This is much higher than that of the Health Care Providers & Services sector and significantly higher than that of the Health Care industry. The current valuation for all Indonesia stocks is significantly lower than that of the firm.
Millennium Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Millennium Pharmacon's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Millennium Pharmacon could also be used in its relative valuation, which is a method of valuing Millennium Pharmacon by comparing valuation metrics of similar companies.Millennium Pharmacon is currently under evaluation in current valuation category among its peers.
Millennium Fundamentals
| Return On Equity | 0.0938 | |||
| Return On Asset | 0.0342 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 828.27 B | |||
| Shares Outstanding | 1.27 B | |||
| Shares Owned By Insiders | 87.94 % | |||
| Shares Owned By Institutions | 3.35 % | |||
| Price To Earning | 9.31 X | |||
| Price To Book | 1.16 X | |||
| Price To Sales | 0.10 X | |||
| Revenue | 2.99 T | |||
| Gross Profit | 237.04 B | |||
| EBITDA | 73.6 B | |||
| Net Income | 9.57 B | |||
| Cash And Equivalents | 43.62 B | |||
| Cash Per Share | 34.24 X | |||
| Total Debt | 1.8 B | |||
| Debt To Equity | 257.80 % | |||
| Current Ratio | 1.15 X | |||
| Book Value Per Share | 202.66 X | |||
| Cash Flow From Operations | (18.18 B) | |||
| Earnings Per Share | 19.19 X | |||
| Number Of Employees | 1.09 K | |||
| Beta | 0.75 | |||
| Market Capitalization | 440.8 B | |||
| Total Asset | 1.21 T | |||
| Annual Yield | 0 % | |||
| Net Asset | 1.21 T | |||
| Last Dividend Paid | 1.0 |
About Millennium Pharmacon Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Millennium Pharmacon International's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Millennium Pharmacon using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Millennium Pharmacon International based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Millennium Stock
Millennium Pharmacon financial ratios help investors to determine whether Millennium Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Millennium with respect to the benefits of owning Millennium Pharmacon security.